High-density lipoprotein modulates thrombosis by preventing von Willebrand factor self-Association and subsequent platelet adhesion

Blood

Volumn 127, Issue 5, 2016, Pages 637-645

  Chung, Dominic W ^a,b   Chen, Junmei ^a   Ling, Minhua ^a   Fu, Xiaoyun ^a,b   Blevins, Teri ^a   Parsons, Scott ^a   Le, Jennie ^a   Harris, Jeff ^a   Martin, Thomas R ^c   Konkle, Barbara A ^a,b   Zheng, Ying ^d   Lopez, Jose A ^a,b  

^a BloodWorks Research Institute   (United States)

^b Department of Biochemistry ^*  (United States)

^c Division of Pulmonary and Critical Care   (United States)

^d University of Washington   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; MONOMER; POLYMER; VON WILLEBRAND FACTOR;

ADSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL OCCLUSION; CELL SURFACE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PATHOGENESIS; PLASMA; PRIORITY JOURNAL; SEPSIS; SHEAR STRESS; THROMBOCYTE ADHESION; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; ANIMAL; C57BL MOUSE; CHEMISTRY; CYTOLOGY; METABOLISM; PROTEIN MULTIMERIZATION; THROMBOCYTE;

ANIMALS; APOLIPOPROTEIN A-I; BLOOD PLATELETS; HUMANS; LIPOPROTEINS, HDL; MICE, INBRED C57BL; PLATELET ADHESIVENESS; PROTEIN MULTIMERIZATION; THROMBOCYTOPENIA; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 84958095360     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-09-599530     Document Type: Article

References (47)

1. Moake JL. Thrombotic thrombocytopenic purpura: survival by "giving a dam". Trans Am Clin Climatol Assoc. 2004;115:201-219.
2. Sadler JE, Moake JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2004;2004:407-423.
3. Ware LB, Conner ER, Matthay M.A. von Willebrand factor antigen is an independent marker of poor outcome in patients with early acute lung injury. Crit Care Med. 2001;29(12): 2325-2331.
4. Angchaisuksiri P. Coagulopathy in malaria. Thromb Res. 2014;133(1):5-9.
5. Chen J, Hobbs WE, Le J, Lenting PJ, de Groot PG, Ĺopez JA. The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma. Blood. 2011; 117(13):3680-3683.
6. Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002; 100(12):4033-4039.
7. Schwameis M, Schörgenhofer C, Assinger A, Steiner MM, Jilma B. VWF excess and ADAMTS13 deficiency: A unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP. Thromb Haemost. 2015;113(4):708-718.
8. Savage B, Sixma JJ, Ruggeri ZM. Functional self-Association of von Willebrand factor during platelet adhesion under flow. Proc Natl Acad Sci USA. 2002;99(1):425-430.
9. Zheng Y, Chen J, Ĺopez JA. Flow-driven assembly of VWF fibres and webs in in vitro microvessels. Nat Commun. 2015;6:7858-7868.
10. Dayananda KM, Singh I, Mondal N, Neelamegham S. von Willebrand factor selfassociation on platelet GpIbalpha under hydrodynamic shear: effect on shear-induced platelet activation. Blood. 2010;116(19): 3990-3998.
11. Barg A, Ossig R, Goerge T, et al. Soluble plasmaderived von Willebrand factor assembles to a haemostatically active filamentous network. Thromb Haemost. 2007;97(4):514-526.
12. Ganderton T, Wong JW, Schroeder C, Hogg PJ. Lateral self-Association of VWF involves the Cys2431-Cys2453 disulfide/dithiol in the C2 domain. Blood. 2011;118(19):5312-5318.
13. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell. 1996; 84(2):289-297.
14. Huang J, Roth R, Heuser JE, Sadler JE. Integrin a(v)b(3) on human endothelial cells binds von Willebrand factor strings under fluid shear stress. Blood. 2009;113(7):1589-1597.
15. Schiviz A, Wuersch K, Piskernik C, et al. A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13. Blood. 2012;119(25):6128-6135.
16. Magnani A, Barbucci R, Lamponi S, et al. Two-step elution of human serum proteins from different glass-modified bioactive surfaces: A comparative proteomic analysis of adsorption patterns. Electrophoresis. 2004;25(14): 2413-2424.
17. Drew BG, Fidge NH, Gallon-Beaumier G, Kemp BE, Kingwell BA. High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation. Proc Natl Acad Sci USA. 2004;101(18):6999-7004.
18. Matsushita K, Morrell CN, Cambien B, et al. Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor. Cell. 2003; 115(2):139-150.
19. Zheng Y, Chen J, Craven M, et al. In vitro microvessels for the study of angiogenesis and thrombosis. Proc Natl Acad Sci USA. 2012; 109(24):9342-9347.
20. Ĺopez JA, Zheng Y. Synthetic microvessels. J Thromb Haemost. 2013;11(Suppl 1):67-74.
21. Chen J, Fu X, Wang Y, et al. Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13. Blood. 2010;115(3):706-712.
22. Jayaraman S, Cavigiolio G, Gursky O. Folded functional lipid-poor apolipoprotein A-I obtained by heating of high-density lipoproteins: relevance to high-density lipoprotein biogenesis. Biochem J. 2012;442(3):703-712.
23. Sakata N, Hoshii Y, Nakamura T, et al. Colocalization of apolipoprotein AI in various kinds of systemic amyloidosis. J Histochem Cytochem. 2005;53(2):237-242.
24. Koldamova RP, Lefterov IM, Lefterova MI, Lazo JS. Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A b aggregation and toxicity. Biochemistry. 2001; 40(12):3553-3560.
25. McCarty OJ, Conley RB, Shentu W, et al. Molecular imaging of activated von Willebrand factor to detect high-risk atherosclerotic phenotype. JACC Cardiovasc Imaging. 2010;3(9): 947-955.
26. Theilmeier G, Michiels C, Spaepen E, et al. Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood. 2002;99(12): 4486-4493.
27. Methia N, Andŕe P, Denis CV, Economopoulos M, Wagner DD. Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood. 2001;98(5):1424-1428.
28. Massberg S, Brand K, Grüner S, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med. 2002; 196(7):887-896.
29. Jin SY, Tohyama J, Bauer RC, Cao NN, Rader DJ, Zheng XL. Genetic ablation of Adamts13 gene dramatically accelerates the formation of early atherosclerosis in a murine model. Arterioscler Thromb Vasc Biol. 2012;32(8): 1817-1823.
30. De Meyer SF, Stoll G, Wagner DD, Kleinschnitz C. von Willebrand factor: An emerging target in stroke therapy. Stroke. 2012;43(2):599-606.
31. Walldius G, Jungner I. Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke. Curr Opin Cardiol. 2007;22(4):359-367.
32. Bockmeyer CL, Reuken PA, Simon TP, et al. ADAMTS13 activity is decreased in a septic porcine model. Significance for glomerular thrombus deposition. Thromb Haemost. 2011; 105(1):145-153.
33. Wu KK, Hall ER, Papp A. Prostacyclin stabilising factor deficiency in thrombotic thrombocytopenic purpura. Lancet. 1982;1(8269):460-461.
34. Yui Y, Aoyama T, Morishita H, Takahashi M, Takatsu Y, Kawai C. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I. J Clin Invest. 1988;82(3):803-807.
35. Bobbio-Pallavicini E, Porta C, Tacconi F, et al; Italian Cooperative Group for Thrombotic Thrombocytopenic Purpura. Intravenous prostacyclin (as epoprostenol) infusion in thrombotic thrombocytopenic purpura. Four case reports and review of the literature. Haematologica. 1994;79(5):429-437.
36. Ferrari S, Scheiflinger F, Rieger M, et al; French Clinical and Biological Network on Adult Thrombotic Microangiopathies. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood. 2007;109(7): 2815-2822.
37. Barlage S, Gnewuch C, Liebisch G, et al. Changes in HDL-Associated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation. Intensive Care Med. 2009;35(11):1877-1885.
38. Simpson DC, Kabyemela E, Muehlenbachs A, et al. Plasma levels of apolipoprotein A1 in malaria-exposed primigravidae are associated with severe anemia. PLoS One. 2010;5(1):e8822.
39. Ozturk OH, Can Y, Yonden Z, et al. Lipoprotein subfraction profile and HDL-Associated enzymes in sickle cell disease patients. Lipids. 2013;48(12): 1217-1226.
40. Tumblin A, Tailor A, Hoehn GT, et al. Apolipoprotein A-I and serum amyloid A plasma levels are biomarkers of acute painful episodes in patients with sickle cell disease. Haematologica. 2010;95(9):1467-1472.
41. Guo L, Ai J, Zheng Z, et al. High density lipoprotein protects against polymicrobe-induced sepsis in mice. J Biol Chem. 2013;288(25): 17947-17953.
42. Nossent AY, Van Marion V, Van Tilburg NH, et al. von Willebrand factor and its propeptide: The influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost. 2006;4(12):2556-2562.
43. Payne AB, Miller CH, Hooper WC, Lally C, Austin HD. High factor VIII, von Willebrand factor, and fibrinogen levels and risk of venous thromboembolism in blacks and whites. Ethn Dis. 2014;24(2):169-174.
44. Brill A, Fuchs TA, Chauhan AK, et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood. 2011;117(4):1400-1407.
45. Chauhan AK, Kisucka J, Lamb CB, Bergmeier W, Wagner DD. von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins. Blood. 2007; 109(6):2424-2429.
46. Joglekar MV, Ware J, Xu J, Fitzgerald ME, Gartner TK. Platelets, glycoprotein Ib-IX, and von Willebrand factor are required for FeCl(3)-induced occlusive thrombus formation in the inferior vena cava of mice. Platelets. 2013;24(3):205-212.
47. Brill A, Yesilaltay A, De Meyer SF, et al. Extrahepatic high-density lipoprotein receptor SR-BI and apoA-I protect against deep vein thrombosis in mice. Arterioscler Thromb Vasc Biol. 2012;32(8):1841-1847.